Acknowledgement
Supported by : Beijing Municipal Administration of Hospitals
References
- Leitner L, Walter M, Freund P, Mehnert U, Michels L, Kollias S, et al. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity. BMC Urol 2014;14:68. https://doi.org/10.1186/1471-2490-14-68
- Tetreault LA, Karadimas S, Wilson JR, Arnold PM, Kurpad S, Dettori JR, et al. The natural history of degenerative cervical myelopathy and the rate of hospitalization following spinal cord injury: an updated systematic review. Global Spine J 2017;7(3 Suppl):28S-34S.
- Hu HZ, Granger N, Jeffery ND. Pathophysiology, clinical importance, and management of neurogenic lower urinary tract dysfunction caused by suprasacral spinal cord injury. J Vet Intern Med 2016;30:1575-88. https://doi.org/10.1111/jvim.14557
- Schops TF, Schneider MP, Steffen F, Ineichen BV, Mehnert U, Kessler TM. Neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury: long-term urodynamic findings. BJU Int 2015;115 Suppl 6:33-8. https://doi.org/10.1111/bju.13085
- Andy UU, Harvie HS, Smith AL, Propert KJ, Bogner HR, Arya LA. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 2015;34:424-8. https://doi.org/10.1002/nau.22605
- Fergany LA, Shaker H, Arafa M, Elbadry MS. Does sacral pulsed electromagnetic field therapy have a better effect than transcutaneous electrical nerve stimulation in patients with neurogenic overactive bladder? Arab J Urol 2017;15:148-52. https://doi.org/10.1016/j.aju.2017.01.007
- Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med 2013;36:402-19. https://doi.org/10.1179/2045772313Y.0000000116
- Yan HL, Zong HT, Cui YS, Li N, Zhang Y. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials. Transplant Proc 2014;46:1302-13. https://doi.org/10.1016/j.transproceed.2014.02.010
- Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 2013;30:819-33. https://doi.org/10.1007/s12325-013-0054-z
- Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord 2013;51:487-90. https://doi.org/10.1038/sc.2012.180
- Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol 2013;31:1469-74. https://doi.org/10.1007/s00345-012-0984-0
- Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013;32:242-9. https://doi.org/10.1002/nau.22293
- Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-50. https://doi.org/10.1016/j.eururo.2011.07.002
- Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9. https://doi.org/10.1016/j.juro.2012.01.125
- Chen SF, Chang CH, Kuo HC. Clinical efficacy and changes of urothelial dysfunction after repeated detrusor botulinum toxin A injections in chronic spinal cord-injured bladder. Toxins (Basel) 2016 May 30;8(6). pii: E164. https://doi.org/10.3390/toxins8060164.
- Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, et al. Combined detrusortrigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 2016;54:46-50. https://doi.org/10.1038/sc.2015.143
- Sengoku A, Okamura K, Kimoto Y, Ogawa T, Namima T, Yamanishi T, et al. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multiinstitutional experience in Japan. Int J Urol 2015;22:306-9. https://doi.org/10.1111/iju.12668
- Chen YC, Kuo HC. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients. Neurourol Urodyn 2014;33:129-34. https://doi.org/10.1002/nau.22395
- Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 2012;50:904-7. https://doi.org/10.1038/sc.2012.76
- Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord 2011;49:659-64. https://doi.org/10.1038/sc.2010.179
- Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613-8. https://doi.org/10.1016/j.eururo.2007.08.039
- Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 2005;86:2114-8. https://doi.org/10.1016/j.apmr.2005.06.008
- Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 2010;184:2423-8. https://doi.org/10.1016/j.juro.2010.08.028
- Samal V, Mecl J, Sram J. Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int 2013;91:423-8. https://doi.org/10.1159/000350247
- Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 2011;185:2229-35. https://doi.org/10.1016/j.juro.2011.02.004
- Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850-8. https://doi.org/10.1016/j.eururo.2007.04.026
- Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007;88:646-52. https://doi.org/10.1016/j.apmr.2007.02.009
- Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. https://doi.org/10.1097/01.ju.0000162035.73977.1c
- Zakin E, Simpson D. Evidence on botulinum toxin in selected disorders. Toxicon 2018;147:134-40. https://doi.org/10.1016/j.toxicon.2018.01.019
- Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003;61:165-71. https://doi.org/10.1016/S0361-9230(03)00114-X
- Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology 2014;84:1044-8. https://doi.org/10.1016/j.urology.2014.07.046
- Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004;45:987-93. https://doi.org/10.1016/j.neuint.2004.06.001
- Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: A review of the mode of action in migraine. Acta Neurol Scand 2018;137:442-51.
Cited by
- Comparison of performance-related physical fitness and anaerobic power between Korean wheelchair badminton national and backup players vol.15, pp.5, 2018, https://doi.org/10.12965/jer.1938448.224
- Intradetrusor OnabotulinumtoxinA Injections Ameliorate Autonomic Dysreflexia while Improving Lower Urinary Tract Function and Urinary Incontinence-Related Quality of Life in Individuals with Cervical vol.37, pp.18, 2020, https://doi.org/10.1089/neu.2020.7115
- Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer vol.21, pp.15, 2018, https://doi.org/10.2174/138945012115201102115645
- Reduced Reflex Autonomic Responses Following Intradetrusor OnabotulinumtoxinA Injections: A Pre-/Post-study in Individuals With Cervical and Upper Thoracic Spinal Cord Injury vol.12, pp.None, 2018, https://doi.org/10.3389/fphys.2021.796277
- Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case ser vol.4, pp.4, 2021, https://doi.org/10.1002/iju5.12301